JANET COVEY: Open Payments
NPI 1194793224 · HARRISBURG, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,643 in 75 payments from 19 companies in 2025. Trend: 2023 $2,704 · 2024 $1,127 · 2025 $1,643
Food & beverage: $1,643
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $299 |
| Novo Nordisk Inc | 8 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $144 |
| Lilly USA, LLC | 5 | $143 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $95 |
| Neurocrine BioSciences, Inc. | 4 | $76 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Verona Pharma, Inc. | 2 | $50 |
Products named: Wegovy, CAPLYTA, UBRELVY, REXULTI, TRINTELLIX, QULIPTA, Kerendia, ZEPBOUND.
Industry payments across AR — which companies pay providers there.
